104 related articles for article (PubMed ID: 21473286)
1. A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19.
Ureshino N; Aragane N; Nakamura T; Ide M; Mochinaga S; Fukushima N; Hayashi S; Sueoka E; Kimura S
Oncol Res; 2011; 19(3-4):111-4. PubMed ID: 21473286
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
[TBL] [Abstract][Full Text] [Related]
3. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
4. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Yi L; Lin G; Zhang K; Wang L; Zhang R; Xie J; Li J
PLoS One; 2016; 11(1):e0148081. PubMed ID: 26820647
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel, fully-automated genotyping system: principle and applications.
Suzuki S; Komori M; Hirai M; Ureshino N; Kimura S
Sensors (Basel); 2012 Dec; 12(12):16614-27. PubMed ID: 23208557
[TBL] [Abstract][Full Text] [Related]
6. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Schulz C; Boeck S; Heinemann V; Stemmler HJ
Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
Yoshihama T; Hirasawa A; Nomura H; Akahane T; Nanki Y; Yamagami W; Kataoka F; Tominaga E; Susumu N; Mushiroda T; Aoki D
Jpn J Clin Oncol; 2017 Feb; 47(2):170-174. PubMed ID: 28173214
[TBL] [Abstract][Full Text] [Related]
10. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.
Hasegawa Y; Sarashina T; Ando M; Kitagawa C; Mori A; Yoneyama M; Ando Y; Shimokata K
Clin Chem; 2004 Aug; 50(8):1479-80. PubMed ID: 15277366
[No Abstract] [Full Text] [Related]
11. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
12. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M; Hasegawa Y; Ando Y
Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
[TBL] [Abstract][Full Text] [Related]
13. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
15. [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
Okazaki K; Watanabe T; Saito I; Murayama J
Yakugaku Zasshi; 2012; 132(2):231-6. PubMed ID: 22293705
[TBL] [Abstract][Full Text] [Related]
16. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Hasegawa Y; Ando Y; Shimokata K
Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027
[TBL] [Abstract][Full Text] [Related]
17. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
Bosó V; Herrero MJ; Bea S; Galiana M; Marrero P; Marqués MR; Hernández J; Sánchez-Plumed J; Poveda JL; Aliño SF
Drug Metab Dispos; 2013 Feb; 41(2):480-7. PubMed ID: 23175667
[TBL] [Abstract][Full Text] [Related]
18. UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Innocenti F
Clin Adv Hematol Oncol; 2005 Nov; 3(11):843-4. PubMed ID: 16491625
[No Abstract] [Full Text] [Related]
19. Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.
Tadje M
Oncol Nurs Forum; 2014 Jul; 41(4):443-4. PubMed ID: 24969255
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango?
O'Donoghue ML
Circulation; 2011 Feb; 123(5):468-70. PubMed ID: 21262991
[No Abstract] [Full Text] [Related]
[Next] [New Search]